Elisi Gian Marco, Santucci Matteo, D'Arca Domenico, Lauriola Angela, Marverti Gaetano, Losi Lorena, Scalvini Laura, Bolognesi Maria Laura, Mor Marco, Costi Maria Paola
Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Cancers (Basel). 2018 Sep 14;10(9):329. doi: 10.3390/cancers10090329.
Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway's terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds.
药物重新利用是一种快速且成熟的方法,用于研究新的活性化合物,绕过药物发现过程漫长的流程。临床实践中的几种药物已被报道可调节主要的Hippo信号通路的终端效应器,即YAP(Yes1相关蛋白)、TAZ(具有PDZ结合基序的转录共激活因子)和TEAD(转录增强关联结构域),它们直接参与细胞生长和组织稳态的调节。由于已知该信号通路与细胞信号通路存在许多相互作用现象,人们已做出诸多努力来了解其在肿瘤学中的重要性。此外,这对于获得新的分子工具和潜在治疗资产可能具有重要意义。在本综述中,我们讨论了最知名化合物(临床批准药物或研究性药物)的主要作用机制,这些化合物能够与Hippo信号通路相互作用并对其进行调节,作为发现新的潜在先导化合物的一种有吸引力的策略。